Effects of Lacticaseibacillus Rhamnosus LRa05 on Bacterial Vaginosis and Ovarian Function in Women

Launched by WECARE PROBIOTICS CO., LTD. · Feb 6, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a specific bacteria called Lacticaseibacillus rhamnosus LRa05 on women who have a condition known as bacterial vaginosis (BV). BV is an imbalance of bacteria in the vagina that can cause symptoms like unusual discharge and odor. The researchers want to see if adding this bacteria to standard antibiotic treatment can help improve the cure rate, reduce how often BV comes back, and positively change the vaginal bacteria for women with this condition.

To participate in the study, women must be between the ages of 18 and 65, currently sexually active, and meet certain health criteria, such as having a specific score indicating BV. Women who have other vaginal infections or certain health issues, are planning to get pregnant, or have used antibiotics recently may not be eligible. If you join the trial, you can expect to receive treatment and be monitored for how well it works. This study is currently not recruiting participants, so it’s important to check back later for updates.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. 18 to 65 years old, sexual activity, premenopausal women;
• • 2. Nugent score for diagnosing BV ≥7;
• • 3. Signed informed consent.
• Exclusion Criteria:
• • 1. Mixed vaginitis, such as vulvovaginal candidiasis (VVC), Trichomonas vaginalis (TV) infection, Chlamydia trachomatis (CT) infection or gonococcal vaginitis;
• • 2. history of systemic organic disease or psychiatric illness;
• • 3. Planning pregnancy, breastfeeding, menstruation;
• • 4. within 5 days of the onset of the disease, any antibiotics have been used;
• • 5. long-term use of contraceptives or immunosuppressants;
• • 6. Allergic constitution or hypersensitivity to known components of the study drug.